Skip to content

Study · Animal study (in vivo) · mouse · 2019

3 results

Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation.

Welch NG, Mukherjee S, Hossain MA, Praveen P, Werkmeister JA, Wade JD, Bathgate RAD, Winkler DA, Thissen H

ACS applied materials & interfaces2 Dec 2019Cited by 9 (Europe PMC)

PMID31713411 (opens in a new tab)DOI10.1021/acsami.9b17859 (opens in a new tab)PepBankPUB-31713411
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, B7‑33-releasing PLGA coatings reduced capsule thickness by 49.2% versus coatings without peptide over 6 weeks.

    In plain wordsIn mice, B7‑33-releasing coatings reduced implant capsule thickness by 49.2% compared with coatings without peptide over 6 weeks.

    Peptide
    B7-33 (single-chain relaxin-2 analog)
    Outcome
    DecreaseFibrotic capsule thickness
    Study

    mousen: not reported in source

    Subcutaneous PLGA-coated polypropylene implants
    Comparator
    PLGA-coated polypropylene without B7-33
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated · subcutaneous implant · 6 weeksAs given in this study (mouse).

    Measurements

    Capsule thickness reduction
    49.2%
    versus coating without peptide

    Source sentences

    Summary
    Subcutaneous implantation of PLGA-coated polypropylene samples in mice with and without the peptide demonstrated a marked reduction in capsule thickness (49.2%) over a 6 week period.
  2. 02LabIn vitro (cells)Activity measurement

    In a reporter cell assay, B7‑33 released from PLGA coatings retained RXFP1 activity.

    In plain wordsIn cells, B7‑33 from PLGA coatings retained activity at the RXFP1 receptor.

    Peptide
    B7-33 (single-chain relaxin-2 analog)
    Outcome
    Not applicableRetained RXFP1 activity
    Study

    n: not reported in source

    In vitro reporter cell assay
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    an in vitro reporter cell assay was used to demonstrate that B7-33 retains activity against the relaxin family peptide receptor 1 (RXFP1).

Studies that did not test the peptide alone1

In this study, B7-33 (single-chain relaxin-2 analog) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking B7-33 (single-chain relaxin-2 analog).

  1. 03LabNot a test of B7-33 (single-chain relaxin-2 analog) aloneIn vitro (cell-free)Pharmacokinetics

    In laboratory tests, PLGA coatings demonstrated controlled release of B7‑33.

    In plain wordsIn lab tests, PLGA coatings released B7‑33 in a controlled manner.

    Peptide
    B7-33 (single-chain relaxin-2 analog)
    Outcome
    Not applicableControlled peptide release
    Study

    n: not reported in source

    PLGA coatings
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    While in vitro protein quantification was used to demonstrate controlled release of the antifibrotic peptide B7-33 from PLGA coatings,

    In this study, B7-33 (single-chain relaxin-2 analog) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking B7-33 (single-chain relaxin-2 analog).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.